Researchers from LKS Faculty of Medicine, The University of Hong Kong (HKUMed), have identified a new combination of two drugs to treat liver cancer, expanding treatment options for hepatocellular carcinoma and reducing the risk of drug resistance. This study leveraged on their CombiGEM-CRISPR v2.0 screening platform1 to expedite the search among the many possible drug combinations to inhibit druggable targets in the genome for treating HCC. The findings are now published in Cancer Research [link to the publication].
This research was led by Dr. Alan Wong Siu-lun, Assistant Professor of the School of Biomedical Sciences, HKUMed and Principal Investigator of the Centre for Oncology and Immunology (COI) together with Dr. Stephanie Ma, Associate Professor of the School of Biomedical Sciences, HKUMed, as co-corresponding authors.
For the original HKU press release, please click here.